Product Images Fulvestrant

The text seems to be a comparison of two treatments for cancer, fulvestrant alone or fulvestrant in combination with palbociclib. The graph shows the probability of progression-free survival (%) over the course of several months for each treatment group. The numbers below the graph suggest the number of patients at risk over time for each treatment group.*

This document reports survival probabilities of two treatment groups (Fulvestrant + Palbociclib and Fulvestrant + Placebo) for a specific period of time (0 to 54 months) based on the number of patients at risk. The percentage values of survival probabilities are not available due to the 's inability to read information.*

This is a survival plot of two treatment groups, Fulvestrant plus Abemaciclib (N=446) and Fulvestrant plus Placebo (N=223), showing the percentage of survival probability over time (in months) on the x-axis. Unfortunately, additional information is not available due to errors in the text.*

Fulvestrant Injection is a medication that comes in a 250 mg/5 mL (50 mg/mL) dosage and is only for intramuscular use. It contains two single-dose prefilled syringes, and both must be used to receive the 500 mg dose. The medication is indicated to treat breast cancer. Some of the important information available include the barcode, expiry date, and other descriptive details.*

This is a description for a medication called Fulvestrant Injection. The medication comes in a pre-filled syringe, with each syringe containing 250 mg/5 mL or 50 my/ml of the medication. The syringe is for intramuscular use only and should be protected from light. To receive the full 600 mg dose, both single-dose prefilled syringes should be administered. The manufacturer is Amneal Pharmaceuticals and the medication has an NDC number of 70121-1463-2. The rest of the text appears to be a mix of random characters and not useful in describing the medication.*

This is a graph that shows the progression-free survival of patients who were given either fulvestrant 250 mg or fulvestrant 500 mg. The graph indicates the number of patients at risk at different time intervals ranging from 0 to 45 months. The x-axis shows the time intervals while the y-axis shows the number of patients at risk.*